James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, ...(ding to Dr. Wittliff Advantages of the ...)

Date:10/28/2008

ding to Dr. Wittliff, "Advantages of the Ziplex automated system to our research include retention of tissue biopsy custody and the rapid, reproducible analyses of gene subsets to investigate breast cancer behavior in order to identify clinically relevant molecular signatures."

Dr. Wittliff was among the first investigators to prove that the expression of estrogen receptors in breast cancer predicted a patient's response to hormone therapy. This finding led to collaborations with the National Surgical Adjuvant Breast Project (NSABP), establishing Tamoxifen as adjuvant therapy for breast cancer and use of receptor proteins as tissue biomarkers of a patient's prognosis and response. With NEN/Dupont, Dr. Wittliff developed the original FDA-approved kits for assessing receptors in biopsies. His laboratory was designated the National Reference Facility for performing quality assurance (QA) surveys of receptor testing for historical clinical trials in North America and for establishing the College of American Pathologists QA Surveys. In recognition of his contributions to medicine, the University of Innsbruck, Austria, awarded Dr. Wittliff, Doctor of Medicine honoris causa. The American Association for Clinical Chemistry honored him with an award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research; he is also the recipient of the Distinguished Scientist's Award by the Clinical Ligand Assay Society. In 2004, the American Cancer Society recognized his lifetime achievements with the Goldsmith Research Excellence Award. His research team is now working with Xceed to develop clinically related tests for breast and other cancers using its proprietary Ziplex System. Dr. Wittliff's discoveries and development of a unique tumor marker database resulted in the filing of new patents for the University of Louisville and the licensing of his technologies.

About Xceed Molecular (http://ww
'/>"/>

SOURCE Xceed Molecular Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
2. Orchid Cellmark Appoints James F. Smith Chief Financial Officer
3. Immunotec Inc. announces appointment of President & CEO James A. Northrop
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. James Webb Space Telescope marks successful completion
6. IRIDEX Announces James Mackaness Will Be Chief Financial Officer
7. Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board
8. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
9. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
10. Warner Chilcott Reports the Death of Its Director James Andress
11. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group